Michael Fossel Michael is President of Telocyte

July 4, 2018

Aging and Disease: 2.8 Cell Senescence, Changes In Molecular Turnover, Extracellular Molecules

The human body contains perhaps a bit short of 40 trillion cells, which is an impressive number, yet a large part of our body – a quarter to a third, depending how you measure it – isn’t intracellular, but extracellular. This includes not only the fluids within the blood and lymphatic spaces, but the space that lies between our cells, even in “solid” tissue. This extracellular space is just as critical – and as it turns out, just as dynamic – as our intracellular space.

The extracellular space has cells within it, for example the fibroblasts in our dermis, the lymphocytes wandering about in our lymphatic system, and the red and white (and other) cells circulating in our blood streams, but if we ignore all of these cells for a moment, we find that the extracellular space is still a complex place. It is replete with important molecules, including electrolytes and proteins (and many others), and these molecules are continually being “recycled”, much as the intracellular molecules are.

The extracellular space is not a quiet place and certainly not a place where protein molecules can quietly “retire” for a few decades. To the contrary, the molecules come and go, subject to continual degradation and replacement. Aging doesn’t occur simply because molecules “sit around and fall apart”. Aging occurs because molecules aren’t turned over as quickly as we age.

Looking solely at human skin – and then solely at a few of the dozens of important molecules that play a role – we find two well-known molecules that are worth focusing on: collagen and elastin. We will simplify our discussion by looking just at the skin, just at collagen and elastin, and just at both proteins generically, intentionally ignoring the multiple subtypes of both collagen and elastin. We will also simplify our discussion by ignoring the water, electrolytes, immune proteins, enzymes, hormones, and various other structural proteins (keratin, muscle, bony matrix, fibronectin, laminins, etc.) that we might discuss.

Let’s focus on what happens to the collagen and elastin in our skin as we age.

Both collagen and elastin are familiar to most of us, as well as to anyone who has ever watched advertisements for skin care products. Collagen is a long, chain-like protein that provides strength and some cushioning throughout the body, including the skin. It is collagen that keeps your skin from pulling apart, providing resistance to stress. In addition to skin, collagen is also found in cartilage, tendons, bones, ligaments, and just about everywhere else. Elastin is – as the name suggests – and elastic molecule that allows skin (and other tissues) to return to its original position when it has been deformed. You might think of collagen as chain that has strength and elastin as a rubber band that stretches. Collagen prevents too much deformation, while elastin pulls skin back after slight deformations.

As we age, both of these fail. Collagen breaks and our skin becomes more fragile and prone to damage from slight impacts or friction. Elastin breaks and our skin sags and no longer “bounces back”. As both of these fail over time, we form wrinkles, although these are only one of the obvious cosmetic changes that occur. Skin loses both strength (collagen) and elasticity (elastin) over time. Why?

Whether you are six or sixty, your collagen and elastin molecules are steadily breaking down and failing. The difference is not the rate of damage, but the rate of turnover. This is the rate at which molecules – such as collagen and elastin — are recycled and replaced. In young skin, collagen turnover can be as high as 10% per day, but the rate of turnover falls steadily with chronological age, or more specifically, with cell aging. As cells are lost and replaced by cell division, the telomeres shorten, gene expression changes, and molecular turnover slows down. The older your cells, the slower the rate at which they replace damaged extracellular proteins, whether collagen, elastin, or any other protein (such as beta amyloid in the elderly patient with Alzheimer’s disease). No wonder our skin becomes fragile, loses elasticity, and develops wrinkles.
Despite the advertising world, none of these changes are amenable to moisturizers, protein injections, serums, creams, or a host of other “miracle anti-aging products” that tout the ability to erase wrinkles, rejuvenate skin, and restore lost beauty.

There is, however, one intervention that would be effective: to reset gene expression and upregulate molecular turnover, so that key molecules, such as collagen and elastin, are more rapidly turned over, with the result that damaged molecules no longer accumulate, but are replaced more quickly. The key to extracellular aging isn’t the damage, but the rate of turnover. The practical implication is that whether we are talking about collagen, elastin, beta amyloid, or dozens of other types of extracellular protein, we can effectively intervene by resetting gene expression. Whether we are looking at skin, joints, bone, or brains, the potential is an innovative and effective intervention for age-related problems.

Next Time: 2.9 Cell Senescence And Tissue Aging

7 Comments »

  1. No argument from me on the futility of trying to turn back time by addressing the degradation of only a few molecules – whether they are elastic, collagen or hyraluronic acid, etc. – or on the huge potential of fully resetting gene expression by re-elongating telomeres to solve this riddle. But the important question for all of us waiting on the side-lines, is will this ever by affordable for the normal man or woman? And will this be achieved via gene therapy (seems unlikely in the near future given the current huge costs in this space), or is there any possibility of a simpler, drug-like approach?

    Comment by Mark — July 6, 2018 @ 4:33 am

  2. Small molecular approaches will never — by their very nature — achieve the effects that can be achieved via TGT (telomerase gene therapy). As for the costs, a number of factors will make this approach relatively cheap and cost effective. In the case of Alzheimer’s alone, we estimate that we can undercut the yearly costs alone by over 90%, while doing so with a single therapy (i.e., one injection every several years) that is effective in preventing and reversing (much of the cognitive decline seen in) Alzheimer’s. Similar savings can be effected in age-related vascular disease (e.g., atherosclerosis, stroke, MI, PVD, CAD, etc.). Most of the savings occur because TGT obviates the need for any other, more-expensive and less effective intervention. In addition, however, gene therapy costs fall for two reasons: 1) the majority of the GT costs occur in the initial “gearing up” phase rather than in continued production and 2) technical advances and economies-of-scale are already lowering costs among our vendors and other vendors globally. Putting the cost into practical terms, anticipated costs will be lower than the costs of an annual health insurance premium (or equivalent annual tax costs to support NHS or other national systems).

    Comment by webmaster — August 18, 2018 @ 1:16 pm

  3. I feel many people are trying to post, but are unable due to server errors… could you please look into that ?

    Comment by Alex Dumitru — July 11, 2018 @ 11:25 am

  4. Alex:

    GoDaddy was upgrading the server. Sorry! Let me know if you still have problems.

    Michael

    Comment by webmaster — July 13, 2018 @ 9:17 am

  5. I’d like a reply to Nark’s question on affordability. PdH

    Comment by Paul d'Heilly — July 18, 2018 @ 10:35 am

  6. I am trying to understand how the shortening of telomeres is effecting gene expression. Can anybody explain this in detail. I also understand gene expression changes well before the Hayflick limit is reached. Does this mean gene expression changes immediately after the first cell division?

    Thank you

    Comment by Stefan — August 18, 2018 @ 11:59 am

  7. Well you should ask. Although we’ve filled in many details, the discussion in my Oxford University Press textbook on this topic (Cells, Aging, and Human Disease) remains a good summary of what we (don’t) know. We do know that as the telomere loses base pairs, there is a gradual change not only in local (i.e., peritelomeric) gene expression, but changes in gene expression throughout the rest of the chromosome, as well as other chromosomes. The changes in gene expression, like the process of cell senescence in general, are not all-or-nothing, but are gradual, insidious, and pervasive, resulting in wide-spread changes in cell function, including mitochondrial efficacy, lipid membrane integrity, DNA repair, and molecular turnover generally. To answer your questions specifically, yes such changes begin well before the Hayflick limit is reached and probably commence with the earliest cell divisions.

    Comment by webmaster — August 18, 2018 @ 1:09 pm

RSS feed for comments on this post.

Leave a comment

Powered by WordPress